CXADR
coxsackie virus and adenovirus receptor
CXADR; coxsackie virus and adenovirus receptor; coxsackievirus and adenovirus receptor; CAR; HCVADR; CVB3-binding protein; coxsackievirus B-adenovirus receptor; 46 kD coxsackievirus and adenovirus receptor (CAR) protein; HCAR; CAR4/6;
PLA2G2A
phospholipase A2, group IIA (platelets, synovial fluid)
PLA2G2A; phospholipase A2, group IIA (platelets, synovial fluid); phospholipase A2, membrane associated; GIIC sPLA2; enhancing factor; modifier of Min1; group IIA phospholipase A2; secretory group II phospholipase A2; phosphatidylcholine 2-acylhydrolase 2A; non-pancreatic secreted type II phospholipase A2; EF; Mom1; Pla2; sPLA2; sPla2-IIA;
SSX4
synovial sarcoma, X breakpoint 4
SSX4; synovial sarcoma, X breakpoint 4; protein SSX4; CT5.4; MGC12411; Synovial sarcoma X breakpoint 4; OTTHUMP00000024292; OTTHUMP00000216158; cancer/testis antigen 5.4; SSX4B;
MRTO4
mRNA turnover 4 homolog (S. cerevisiae)
MRTO4; mRNA turnover 4 homolog (S. cerevisiae); C1orf33, chromosome 1 open reading frame 33 , MRT4, mRNA turnover 4, homolog (S. cerevisiae); mRNA turnover protein 4 homolog; dJ657E11.4; MRT4; 60S acidic ribosomal protein PO; mRNA turnover 4 homolog; MRT 4; MRT4 mRNA turnover 4 homolog; MRTO 4; Ribosomal protein large P0 like; Ribosomal protein P0 like protein; OTTHUMP00000002580; MRT4, mRNA turnover 4, homolog; C1orf33;
PLXNA1
plexin A1
PLXNA1; plexin A1; NOV; NOVP; PLXN1; PLEXIN-A1; plexin-A1; plexin 1; semaphorin receptor NOV;
SSX1
synovial sarcoma, X breakpoint 1
SSX1; synovial sarcoma, X breakpoint 1; protein SSX1; cancer/testis antigen family 5; member 1; CT5.1; X breakpoint 1; Cancer/testis antigen 5.1; Cancer/testis antigen family 5 member 1; MGC150425; MGC5162; sarcoma, synovial, X chromosome related 1; SSRC; SSX1_HUMAN; Synovial sarcoma; cancer/testis antigen family 5, member 1; sarcoma, synovial, X-chromosome-related 1;
SSX2
synovial sarcoma, X breakpoint 2
SSX2; synovial sarcoma, X breakpoint 2; SSX; protein SSX2; cancer/testis antigen family 5; member 2a; CT5.2a; HD21; HOM MEL 40; MGC3884; MGC15364; MGC119055; sarcoma; synovial; X chromosome related 2; synovial sarcoma; X breakpoint 2; isoform b; X breakpo;
BNIPL
BCL2/adenovirus E1B 19kD interacting protein like
BNIPL; BCL2/adenovirus E1B 19kD interacting protein like; bcl-2/adenovirus E1B 19 kDa-interacting protein 2-like protein; BNIPl 1; BNIPL 2; PP753; Bcl 2/adenovirus E1B 19 kDa interacting protein 2 like protein; BNIP 2 similar; BNIP S; BNIP2 similar; BNIPL1; BNIPL2; BNIPS; BNIP-2 similar; BNIP-S; BNIPL-1; BNIPL-2;
BNIP1
BCL2/adenovirus E1B 19kDa interacting protein 1
BNIP1; BCL2/adenovirus E1B 19kDa interacting protein 1; BCL2/adenovirus E1B 19kD interacting protein 1; vesicle transport protein SEC20; Nip1; SEC20; BCL2 adenovirus E1B 19kD interacting protein 1; BCL2/adenovirus E1B 19 kDa protein-interacting protein 1; MGC41600; OTTHUMP00000161077; OTTHUMP00000161078; OTTHUMP00000161079; OTTHUMP00000223580; SEC20_HUMAN; SEC20L; Transformation-related gene 8 protein; TRG-8; TRG8;
BNIP3L
BCL2/adenovirus E1B 19kDa interacting protein 3-like
BNIP3L; BCL2/adenovirus E1B 19kDa interacting protein 3-like; BCL2/adenovirus E1B 19kD interacting protein 3 like; BCL2/adenovirus E1B 19 kDa protein-interacting protein 3-like; BNIP3a; Nix; NIP3L; NIP3-like protein X; adenovirus E1B19k-binding protein B5; BCL2/adenovirus E1B 19-kd protein-interacting protein 3a; BCL2/adenovirus E1B 19 kDa protein-interacting protein 3A;
SS18
synovial sarcoma translocation, chromosome 18
SS18; synovial sarcoma translocation, chromosome 18; SSXT; protein SSXT; SYT; MGC116875; Protein SYT; SSXT/SSX4v fusion; SSXT_HUMAN; Synovial sarcoma translocated to X chromosome; Synovial sarcoma translocated to X chromosome protein; Synovial sarcoma translocation chromosome 18; SYT SSX1; SYT SSX2; SYT/SSX4v fusion protein; SYTSSX1; SYTSSX2; synovial sarcoma, translocated to X chromosome;
SSX3
synovial sarcoma, X breakpoint 3
SSX3; synovial sarcoma, X breakpoint 3; protein SSX3; CT5.3; MGC119054; Cancer/testis antigen 5.3; MGC14495; SSX3_HUMAN; synovial sarcoma, X breakpoint 3, isoform a;
SYVN1
synovial apoptosis inhibitor 1, synoviolin
SYVN1; synovial apoptosis inhibitor 1, synoviolin; E3 ubiquitin-protein ligase synoviolin; HRD1; KIAA1810; MGC40372;
BNIP3
BCL2/adenovirus E1B interacting protein 3
BNIP3; BCL2/adenovirus E1B interacting protein 3; BCL2/adenovirus E1B 19 kDa protein-interacting protein 3; BCL2/adenovirus E1B interacting protein 1, NIP3; BCL2/adenovirus E1B 19kDa-interacting protein 1, NIP3; BCL2/adenovirus E1B 19 kDa-interacting prot;
LOC442228
similar to dJ22I17.2 (novel protein with EGF-like and laminin G domains)
LOC442228; similar to dJ22I17.2 (novel protein with EGF-like and laminin G domains); similar to dJ22I17.2 (novel protein with EGF-like and laminin G; dJ22I17.2;
BNIP2
BCL2/adenovirus E1B 19kDa interacting protein 2
BNIP2; BCL2/adenovirus E1B 19kDa interacting protein 2; BCL2/adenovirus E1B 19kD interacting protein 2; BCL2/adenovirus E1B 19 kDa protein-interacting protein 2; BNIP 2; Nip2; BNIP-2;
SSX5
synovial sarcoma, X breakpoint 5
SSX5; synovial sarcoma, X breakpoint 5; protein SSX5; SSX5_HUMAN;
SSX2IP
synovial sarcoma, X breakpoint 2 interacting protein
SSX2IP; synovial sarcoma, X breakpoint 2 interacting protein; afadin- and alpha-actinin-binding protein; SSX2-interacting protein; afadin DIL domain-interacting protein; ADIP; FLJ10848; KIAA0923; MGC75026;
SSX4B
synovial sarcoma, X breakpoint 4B
SSX4B; synovial sarcoma, X breakpoint 4B; protein SSX4; OTTHUMT00000056510; Cancer/testis antigen 5.4; CT5.4; MGC119056; MGC12411; MGC169015; MGC169016; SSX4; SSX4A; Synovial sarcoma X breakpoint 4; Synovial sarcoma X breakpoint 4B;
SS18L2
synovial sarcoma translocation gene on chromosome 18-like 2
SS18L2; synovial sarcoma translocation gene on chromosome 18-like 2; SS18-like protein 2; KIAA iso; SYT homolog 2; SS18 like protein 2; Synovial sarcoma translocation gene on chromosome 18 like 2; KIAA-iso;
SS18L1
synovial sarcoma translocation gene on chromosome 18-like 1
SS18L1; synovial sarcoma translocation gene on chromosome 18-like 1; calcium-responsive transactivator; KIAA0693; SS18; SS18-like protein 1; SSXT; synovial sarcoma translocation; SYT homolog 1; CREST; LP2261;
De Novo Protein Design
De novo protein design, also known as "the inverse protein folding problem", is a computational approach to protein design from scratch, rather than using a known protein structure. Identification of a primary sequence that can fold properly in to the desired structural topology forms the basis for ...
Two proteins, ATG12 and ATG5 Might Help People Developing Innovative Cancer Therapies
Scientists at The Scripps Research Institute (TSRI) have found two key subunits within a cell that helps maintaining cell health. They identified how the two proteins help create organelles. Their discoveries make people think about interfering with the formation of these organelles and lead to new ...
Cell: Researchers Found a Novel Rule of Membrane Proteins
Like the teeth of a zipper, the charged amino acids (as the red and blue color show) form connections between protein segments and thus form pores in the cell membrane. Membrane proteins, attached to or associated with themembraneof acellor anorganelle, perform a variety of functions vita...
Scientific Report: Testing DNA Methylation with Novel Assay
According to the Scientific Report, researchers have developed a new, single molecule test for detecting methylated DNA. DNA Methylationis abiochemicalprocess that involves the addition of amethyl groupto thecytosineoradenineDNAnucleotides. Through this way, it regulates gene expressionincell...
Scientists Found Novel Monoclonal Antibody for CLL
Chronic lymphocytic leukemia (CLL) is one kind of blood cancer. It is the second most common type of leukemia in adults. It is also the most common type of blood cancer in America. According to authentic statistics, it is estimated that 16,060 men and women will be diagnosed with and 4,580 men a...
Scientists Innovatively Modified an Approach to Dissect Kinases
The top is a structural model of uniRapR domain which binds small molecule rapamycin. The bottom left depicts inactive state of the protein of interest modified with uniRapR domain. Binding of rapamycin and uniRapR reactivates the protein (bottom right). The approach mentioned here i...
PNAS: Scientists Unveiled a Novel Feature of DEAD-box Proteins
As reported on the Early Edition of the Proceeding of the National Academy of Science on Apr. 29, 2013, scientists have uncovered how DEAD-box proteins and its cofactors can specifically work on other proteins with nonspecific biochemical activity. DEAD-box proteins are a large class of RNA-depen...
Introduction to an Innovative Antibody Selection Method
It is reported in the Cell that researchers have developed a powerful innovative technique to find antibodies, especially therapeutic antibodies. A few years ago, the researchers developed a basic method to select antibodies thatnot only bind to a given target, but also have a desired biolog...
Lipid-based Protein Immobilization—A Novel Membrane Protein Research Tool
Lipid-based Protein Immobilization, or LPI, allows for immobilization and work-up of intact, native membrane proteins. Lipid-based Protein Immobilization allows immobilization of cell vesicles with intact, conformationally correct membrane pr...
Novel Method for Detection of Ovarian Cancer Might Launch Soon
Ovarian cancer is considered to be the most difficult to detect in kinds of cancers. It is difficult to note or detect at early cancer stage, if pain occurs, people might treat it as other symptoms as often been mistaken for other diseases. This makes cancer prevention and control very difficult. D...
A Novel Biomarker for Metabolic Dysfunction and New Hope for Obesity—Protein PAR2
In studies, scientists confirmed that the amount of inflammatory protein PAR2 in overweight/obese humans and mices abdominal adipose tissue show abnormality and they found the common fatty acids in the diet will increase the expression of PA...
Creative BioMart Introduced Its Novel Computer-aided Enzyme Design Services
Scientists aiming at discovering new protein and enzyme now have access to Creative BioMart’s quality computer-aided enzyme design (CAED) services. This enzymatic design service was issued under the rigorous requirements of Creative BioMart to provide world-leading biotech services. The past decades...
Creative BioMart Launched a Novel Service for Transcription Factor Assay
When: October 13, 2014 Where: 45-16 Ramsey Road Shirley What: Launch of new service Introduction: Creative BioMart announced today for the official release of its new service--transcription factor assay service which is backed by various of tools that can meet various of needs and facili...
The 2nd Novel Immunotherapeutics Summit of GTC
Why Experts from academia and industry to discuss cutting edge research, immuno-strategies and novel findings and therapeutics against various diseases. Representatives from top leaders in the pharmaceutical and biotech industries including Abbott, Bristol-Myer-Squibbs, Johnson Johnso...
The New Diabetes Drug of Novo Nordisk A/S (NVO) Get Approval by FDA
Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care. On Nov. 8, 2012, the Endocrinologic and Metabolic Drugs Advisory Committee of the United States Food and Drug Administration (FDA) completed the New Drug Application (NDA) for insulin degludec...
Worldwide Biotech/Biopharma Executives (From Nov. 7 to Nov. 2, 2012)
On Nov. 7, 2012, Array BioPharma Inc. announced John A. Orwin, chief executive officer of Affymax, Inc., joined the Company's board of directors. On Nov. 6, 2012, Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (APRI) announced that Bassam Damaj, Ph.D., has resigned as a Director, Presid...
Worldwide Biotech/Biopharma Alliance (From Nov. 12 to Otc. 30, 2012)
On Nov. 12, 2012, Caris Life Sciences Enhances Molecular Profiling Service With Addition of ROS1 and MGMT-Methylation Biomarkers. These markers are believed to serve as clinically-important aids in the development of treatment plans for patients with non-small cell lung cancer (NSCLC) and glioblasto...
Worldwide Biotech/Biopharma Alliance (during Nov. 14 and Nov. 12)
On Nov. 14, 2012, Fujifilm Diosynth Biotechnologies added another licensed product to its list of commercial biopharmaceutical products, following the announcement that ThromboGenics' has received FDA approval for the launch of JETREA? (ocriplasmin) in the USA for the treatment of Symptomatic Vitreo...
World Pharma/Clinical Trial Regulatory (From Nov. 29 to Nov. 30)
On Nov. 30, 2012, Exelixis, Inc. (EXEL) announced that the U.S. Food and Drug Administration (FDA) have approved COMETRIQ (cabozantinib) for the treatment of progressive, metastatic medullary thyroid cancer (MTC). COMETRIQ is an inhibitor of multiple receptor tyrosine kinases involved in both normal...
What Biopharmaceutical Innovations and New Drug Discovery Bring?
There is no exact definition for innovation. While there at least should be a substantial improvement and not a small change over what is currently available, for example, the growth and maturation of high throughput screening and microarray technique. The Biopharmaceutical and drug discovery...
